@jmsadowska

a) Engineer b) Scientific communicator c) Pharma analyst d) All of the above My newsletter: https://xitter.cf/t.co/gh9aJL25KV

 Boston
linkedin.com/in/joanna-sadowska-phd/
Joined February 2019
  • Tweets536
  • Following1.1K
  • Followers959
95Media
1/5 BREAKING NEWS: Novartis pays $2B upfront to acquire Synnovation Therapeutics's pan-mutant-selective PI3Kฮฑ inhibitor program โ€” a strategic bet to defend its breast cancer franchise. ๐Ÿงต
1
209
more replies
4/5 The lead asset: SNV4818 โ€” a pan-mutant-selective PI3Kฮฑ inhibitor in Phase 1/2 in breast cancer and solid tumors. Being tested as: โ–ธ Monotherapy โ–ธ + Faslodex โ–ธ + Ibrance
1
132
5/5 Deal expected to close mid-2026. $2B upfront for a Phase 1/2 asset signals how much Novartis values next-gen selectivity โ€” and how competitive the PI3Kฮฑ space is becoming.
91
1/7 These drugs generated the highest sales in 2025 โ€” and 2025 marked a genuine shift in who holds the power. ๐Ÿงต
1
1
2
213
more replies
6/7 Blockbusters still dominate โ€” but the map is being redrawn. Onco-immunology built the last decade. GLP-1s may define the next one.
1
82
7/7 Drop your thoughts below ๐Ÿ‘‡ โ€” Dr Jojo | Follow for pharma & biotech industry news. Share if this was useful.
77
1/6 BIG NEWS: Johnson & Johnson reports an 89% complete response rate with intravesical targeted therapy in early-stage bladder cancer ๐Ÿงต
1
118
more replies
5/6 Phase 1 results: โœ… 89% complete response rate (intermediate-risk) โœ… 83% recurrence-free at 12 months (high-risk) โœ… Median duration of complete response: 18 months
1
59
6/6 Erda-iDRS would be the first precision-based, biology-driven treatment for early-stage bladder cancer. Phase 3 studies (MoonRISe-1 & MoonRISe-3) are ongoing.
54
Which drugs drove the most revenue for pharma giants in 2025? I mapped the top 3 selling medicines across 12 major companies - from $41B to $65B in revenue. Here's what the data tells us ๐Ÿงต
1
2
5
470
more replies
@abbvie deserves a mention. Skyrizi and Rinvoq have more than absorbed the Humira biosimilar erosion - a transition many analysts flagged as an existential risk just a few years ago. That's pipeline execution done right.
1
118
Five companies now sit above $58B in revenue. Scale alone is no longer the differentiator. Pipeline depth and indication expansion are. What stands out to you in this year's data? #pharma #biotech #drjojo Source: Company financial reports, FY2025
79
Load more